Health news
A probiotic lotion had comparable results to 2.5% benzoyl peroxide treatment for acne vulgaris in a randomized controlled trial, study findings of which were published in the Journal of Cosmetic Dermatology. Investigators enrolled patients from…
The prevalence of macrolide resistance among Cutibacterium acnes (C acnes) strains is higher than previously reported, study data published in Frontiers in Public Health suggests. Screening for macrolide resistance in patients with acne may reduce…
Diluted intradermal botulinum toxin A injections (Microbotox) may be effective for treating patients with mild to moderate acne vulgaris and erythematotelangiectatic rosacea, according to findings from a study published in the Journal of Cosmetic Dermatology.…
Despite the range of available pharmacologic therapies for acne, many patients continue to experience lesions, underscoring the need for additional acne management strategies. Patients often report suspected associations between acne flares and various foods or…
Subcision combined with hyaluronic acid (HA) or popoly-L-lactic acid (PLLA) threads may better reduce the appearance of atrophic acne scars than subcision alone, suggests study data published in the Journal of Cosmetic Dermatology. This split-face…
An evidence-based acne guideline from the National Institute for Health and Care Excellence (NICE) provides updated recommendations for managing acne, including both the physical manifestations of the disease as well as its psychological affect. An…
Winlevi® (clascoterone cream 1%) is now available for the topical treatment of acne vulgaris in patients 12 years and older. Winlevi, a topical androgen receptor inhibitor, targets androgen receptors at the application site, inhibiting the…
The Food and Drug Administration has approved system changes to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program for isotretinoin products. The system changes will go into effect starting December 13, 2021 for health…
The Food and Drug Administration has approved Solaris Pharma’s Abbreviated New Drug Application for clindamycin phosphate EQ 1% topical gel, the first generic version of Clindagel® (Bausch Health). Clindamycin phosphate EQ 1% gel is indicated…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021